BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Dennis H. Langer, M.D., J.D. to the Company’s Board as an independent Director, effective May 1, 2021.
Dr. Langer has served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies. He served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy's North American business and was a Senior Vice President of Research and Development at GlaxoSmithKline plc. He is currently a director of the Whitehead Institute for Biomedical Research, Myriad Genetics, Inc. (NASDAQ: MYGN), and several private companies. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.
“Dr. Langer brings an extraordinary depth of experience to the Board of Brooklyn ImmunoTherapeutics,” said Charles Cherington, Chair of the Board of Brooklyn. “Dr. Langer has been a leader in drug and device development and commercialization in both early stage companies and multinational pharmaceutical companies. He has a demonstrated ability to identify promising science that results in transformative therapies. We look forward to Dr. Langer’s contributions as Brooklyn ImmunoTherapeutics advances IRX-2 in the clinic and actively explores opportunities to license leading edge gene editing and cell therapy technology.”
“Brooklyn Immunotherapeutics is well-positioned to improve cancer care with IRX-2, its clinical stage cytokine-based therapy that is currently being evaluated both as a single agent and in combination with other anti-cancer agents in a number of solid tumor indications,” said Dr. Langer. “In addition, I’m excited by the opportunity for Brooklyn to license leading edge technology that could open new avenues for drug development. I look forward to working with the team at Brooklyn ImmunoTherapeutics at such a pivotal time in its development as an innovator in oncology.”
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreement with Factor Bioscience/Novellus.
Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.
